BMS Divests Indonesian OTC Business, Continues Biopharma Consolidation
This article was originally published in The Tan Sheet
Executive Summary
Japanese firm Taisho Pharmaceutical will acquire nearly all shares of Bristol-Myers Squibb's Asian OTC subsidiary
You may also be interested in...
Reckitt Deals Feed OTC Domination Plan
Reckitt Benckiser CEO Rakesh Kapoor plays up the firm’s potential to dominate the fragmented global consumer health product market and says Reckitt is better positioned than big pharma firms to manage OTC businesses. Reckitt continued its emerging markets focus with OTC deals in Latin America and China.
Reckitt Deals Feed OTC Domination Plan
Reckitt Benckiser CEO Rakesh Kapoor plays up the firm’s potential to dominate the fragmented global consumer health product market and says Reckitt is better positioned than big pharma firms to manage OTC businesses. Reckitt continued its emerging markets focus with OTC deals in Latin America and China.
Bristol-Myers Squibb To Sell Australian Manufacturing Facility To Generics Maker Sigma
PERTH, Australia - Bristol-Myers Squibb revealed Sept. 7 that it plans to sell its Australian manufacturing facility in Melbourne to generic drug maker Sigma Pharmaceuticals for roughly AU$60 million. The Melbourne-based plant is the only production facility held by BMS in Australia